



Predicting Stroke Outcomes Using Ankle-Brachial
Index and Inter-Ankle Blood Pressure Difference
Minho Han 1 , Young Dae Kim 1,2 , Jin Kyo Choi 1, Junghye Choi 1, Jimin Ha 1,
Eunjeong Park 3 , Jinkwon Kim 4, Tae-Jin Song 5, Ji Hoe Heo 1,2 and Hyo Suk Nam 1,2,*
1 Department of Neurology, Yonsei University College of Medicine, Seoul 03722, Korea;
umsthol18@yuhs.ac (M.H.); neuro05@yuhs.ac (Y.D.K.); JKSNAIL85@yuhs.ac (J.K.C.); hye07@yuhs.ac (J.C.);
jiminha@yuhs.ac (J.H.); jhheo@yuhs.ac (J.H.H.)
2 Integrative Research Center for Cerebrovascular and Cardiovascular Diseases, Seoul 03722, Korea
3 Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul 03722, Korea;
EUNJEONG-PARK@yuhs.ac
4 Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine,
Yongin-si 16995, Korea; ANTITHROMBUS@yuhs.ac
5 Department of Neurology, Seoul Hospital, Ewha Womans University College of Medicine,
Seoul 07804, Korea; knstar@ewha.ac.kr
* Correspondence: hsnam@yuhs.ac; Tel.: +82-2-2228-1617; Fax: +82-2-393-0705
Received: 17 March 2020; Accepted: 13 April 2020; Published: 15 April 2020


Abstract: Background: This study investigated the association of high ankle-brachial index difference
(ABID) and systolic inter-ankle blood pressure difference (IAND) with short- and long-term outcomes
in acute ischemic stroke patients without peripheral artery disease (PAD). Methods: Consecutive
patients with acute ischemic stroke who underwent ankle-brachial index (ABI) measurement were
enrolled. ABID was calculated as |right ABI-left ABI|. IAND and systolic inter-arm blood pressure
difference (IAD) were calculated as |right systolic blood pressure – left systolic blood pressure|. Poor
functional outcome was defined as modified Rankin Scale score ≥3 at 3 months. Major adverse
cardiovascular events (MACEs) were defined as stroke recurrence, myocardial infarction, or death.
Results: A total of 2901 patients were enrolled and followed up for a median of 3.1 (interquartile range,
1.6–4.7) years. Among them, 2643 (84.9%) patients did not have PAD. In the logistic regression analysis,
ABID ≥ 0.15 and IAND ≥ 15 mmHg were independently associated with poor functional outcome
(odds ratio (OR), 1.970, 95% confidence interval (CI), 1.175-3.302; OR, 1.665, 95% CI, 1.188-2.334,
respectively). In Cox regression analysis, ABID ≥0.15 and IAND ≥ 15 mmHg were independently
associated with MACEs (hazard ratio (HR), 1.514, 95% CI, 1.058-2.166; HR, 1.343, 95% CI, 1.051-1.716,
respectively) and all-cause mortality (HR, 1.524, 95% CI, 1.039-2.235; HR, 1.516, 95% CI, 1.164-1.973,
respectively) in patients without PAD. Conclusion: High ABID and IAND are associated with poor
short-term outcomes, long-term MACE occurrence, and all-cause mortality in acute ischemic stroke
without PAD.
Keywords: ankle-brachial index difference; inter-ankle blood pressure difference; stroke; peripheral
artery disease; outcome
1. Introduction
Blood pressure (BP) ratios and differences between the four limbs can be simultaneously obtained
and calculated with ankle-brachial index (ABI) measurement [1]. Among the ratios and differences,
ABI difference (ABID), systolic inter-ankle blood pressure difference (IAND), and systolic inter-arm
BP difference (IAD) have been reported to be useful in predicting the prognosis in patients with
cardiovascular disease, high-risk populations, and the general population [2,3].
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Lower extremity peripheral artery disease (PAD) is defined by a low ABI, calculated by dividing
the ankle systolic BP by the arm systolic BP. ABI has high specificity and sensitivity for the diagnosis of
PAD [4], and ABI may also provide information beyond PAD. A previous study showed that ABID
≥ 0.15 was an independent risk factor for overall mortality in patients undergoing hemodialysis [5].
However, the prognostic value of ABID in patients with ischemic stroke remains uncertain.
IAD is strongly associated with increased cardiovascular and all-cause mortality [6]. Previous
studies showed that IAND provided additional information to estimate stroke incidence and
cardiovascular mortality beyond IAD [1,3]. To the best of our knowledge, no study has reported the
prognostic impact of IAND on the outcomes of patients with acute ischemic stroke.
A previous study showed that the prevalence of PAD in patients with ischemic stroke was 32%
and the rate of asymptomatic PAD in patients with stroke was 68% [7]. Another study showed that
stroke patients with asymptomatic PAD had an increased risk of recurrent vascular events, including
stroke [8]. Therefore, the prognostic significance needs to be separately assessed in ischemic stroke
patients without PAD.
In this regard, we hypothesized that ABID and IAND are associated with poor short-term
functional outcomes, major adverse cardiovascular events (MACEs), and all-cause mortality in patients
with acute ischemic stroke. Whether the prognostic values of these parameters are valid in acute
ischemic stroke patients without PAD was also investigated.
2. Materials and Methods
2.1. Patients and Evaluation
A hospital-based, retrospective observational study using prospectively collected stroke registry
data was conducted. The Yonsei Stroke Registry collected the data of patients with acute cerebral
infarction or transient ischemic attack (TIA) who presented to the emergency department within 7 days
of symptom onset between January 1, 2007 and June 30, 2013 [9]. Acute cerebral infarction was defined
as sudden onset of acute neurological deficits of presumed vascular etiology lasting 24 h or evidence of
acute infarction on brain computed tomography (CT) or magnetic resonance imaging (MRI). TIA was
diagnosed when a patient had transient (<24 h) neurologic dysfunction of vascular origin and did not
show acute lesions on CT or MRI. Among these candidates, only patients with available four-limb BPs
measured by ABI examination and a cerebral angiographic evaluation using either CT angiography,
MR angiography, or digital subtraction angiography performed during the admission period were
included. Patients were treated by standard treatment protocols based on the guidelines for acute
ischemic stroke [10–13]. Stroke classifications were determined during weekly conferences. Based on a
consensus of three stroke neurologists, stroke subtypes were classified according to the Trial of ORG
10172 in Acute Stroke Treatment (TOAST) classification [14].
2.2. Demographic Characteristics and Risk Factors
We collected data on baseline characteristics, including sex, age, and neurological deficit (National
Institutes of Health Stroke Scale (NIHSS) score) upon admission; presence of risk factors; and laboratory
data (glucose, high-density lipoprotein (HDL), and low-density lipoprotein (LDL)). Hypertension was
defined as resting systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of
≥90 mmHg after repeated measurements during hospitalization or currently taking antihypertensive
medication. Diabetes mellitus was defined as fasting plasma glucose levels of ≥7 mmol/L or taking
an oral hypoglycemic agent or insulin. Current smoking was defined as having smoked a cigarette
within 1 year prior to admission. Congestive heart failure was determined from the history of heart
failure diagnosis, treatment with loop diuretics, and ejection fraction of ≤35% on echocardiography.
Coronary artery disease (CAD) was diagnosed when a patient had a previous history of CAD (acute
myocardial infarction, unstable angina, coronary artery bypass graft, or percutaneous coronary artery
stent/angioplasty) or the presence of significant stenosis (≥50%) in any of the three main coronary
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arteries on multi-slice CT coronary angiography upon admission. Cerebral artery atherosclerosis
(CAA) was defined as occlusion or significant stenosis (≥50%) of any intracranial or extracranial
cerebral artery. PAD was determined if a patient had an ABI of <0.9 or a history of angiographically
confirmed PAD.
2.3. ABI and Brachial-Ankle Pulse Wave Velocity Measurement
ABI and brachial-ankle pulse wave velocity (baPWV) were measured in the supine position
using an automatic device (VP-1000; Colin Co., Ltd., Komaki, Japan), which has been validated
previously [6,15]. This device automatically and simultaneously measures four-limb pulse wave forms
and BP using the oscillometric method. Right ABI was calculated by the ratio of the right ankle SBP
divided by the higher SBP of the arms. Left ABI was calculated by the ratio of the left ankle SBP divided
by the higher SBP of the arms. ABID was calculated as |right ABI-left ABI|. IAND was extracted as
BPs from both legs and calculated as |right ankle SBP-left ankle SBP|. IAD was extracted as BPs from
arms and calculated as |right brachial SBP-left brachial SBP|. BaPWV on each side was automatically
calculated as the transmission distance divided by the transmission time and expressed in centimeters
per second. Transmission distance from the arm to each ankle was automatically calculated according
to the patient’s height. Transmission time was defined as the time interval between the initial increase
of brachial and tibial waveforms. The higher values of baPWV on both sides were used for analysis.
2.4. Follow-Up and Outcome Measures
Patients were followed up in the outpatient clinic or by a structured telephone interview at
3 months and yearly after discharge. Short-term functional outcomes at 3 months were determined
by a structured interview using the modified Rankin Scale (mRS). Poor outcome was defined as an
mRS of ≥3. Deaths among participants from January 1, 2007 to December 31, 2013, were confirmed by
matching the information in the death records and identification numbers assigned to the participants
at birth [16]. We obtained data for the date and causes of death from the Korean National Statistical
Office, which were identified based on death certificates. MACEs were defined as any stroke recurrence,
myocardial infarction occurrence, or death.
2.5. Statistical Analysis
SPSS for Windows (version 23, SPSS, Chicago, IL, USA) was used for the statistical analysis.
Intergroup statistical analyses were performed to compare the demographic characteristics and risk
factors in the whole study population. The statistical significance of intergroup differences was assessed
using the χ2 or Fisher’s exact test for categorical variables and independent two-sample t-test or
Mann–Whitney U-test for continuous variables. Data were expressed as means ± standard deviations
or medians (interquartile ranges (IQRs)) for continuous variables and numbers (%) for categorical
variables. Cutoff values for IAND and IAD were based on those used in the previous study [3].
In elderly people, IAND of ≥15 mmHg and IAD of ≥15 mmHg were cutoff values that could predict
mortality [3]. The cutoff value of ABID of ≥0.15 mmHg was based on a study wherein ABID predicted
the mortality of patients with chronic hemodialysis [5]. Multivariable logistic regression analysis was
performed after adjusting for sex, age, cardiovascular risk factors (hypertension, diabetes mellitus,
hypercholesterolemia, current smoking, congestive heart failure, CAD, CAA, and PAD), and variables
that exhibited a p value of <0.05 in the univariate analysis, to investigate the association of ABID,
IAND, or IAD with short-term functional outcomes. Survival curves were generated according to the
Kaplan–Meier method and compared using the log-rank test. Multivariable Cox proportional hazard
regression was performed to determine independent factors associated with survival after an ischemic
stroke. Subgroup analysis was also performed to confirm that the associations between short- and
long-term outcomes and BP differences were valid in patients without PAD. We analyzed the diastolic
IAND and diastolic IAD separately as supplemental data. All P values were two-tailed, and differences
were considered significant at p < 0.05.
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2.6. Standard Protocol Approval, Registration, and Patient Consent
The Institutional Review Board of Severance Hospital, Yonsei University Health System, approved
this study and waived the need for informed consent because of the retrospective design and
observational nature of this study (approval date: 2020-01-16; approval number: 4-2019-1196).
2.7. Data availability Statement
De-identified participant data are available upon reasonable request.
3. Results
3.1. Patient Demographic and Clinical Characteristics
A total of 3822 patients with acute ischemic stroke or TIA were recruited during the study period.
After exclusions (follow-up loss (n = 154), no ABI measurements (n = 729), hemodialysis of one arm
(n = 16), and TIA (n = 22)), 2901 patients were finally enrolled in this study (Figure 1).
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(mRS of 3‒6;  
n = 582) 
p value 
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Figure 1. Flowchart of participants according to inclusion and exclusion criteria. ABI, ankle brachial
index; mRS; modified Rankin Scale score.
A total of 258 (8.9%) patients had PAD. The mean age was 65.4 ± 12.2 years, and 61.8% were
men. Among them, 582 (20.1%) had poor outcomes (Table 1). Compared with p tients with good
outcomes, those with poor outcomes were older, were more likely to be women, had more severe
initial stroke severity, were less likely to be current smokers, and were more likely to have CAA, PAD,
and a stroke subtype of large artery atherosclerosis (all p values <0.05). For four-limb BP profiles, both
ankle SBP and ABI were lower in patients with poor outcomes than in those with good outcomes (all
p values <0.001). All BP differences including ABID, IAND, and IAD were higher in patients with
poor outcomes than in those with good outcomes (all p values <0.001). Compared with the included
patients, excluded patients were older, were more likely to be women, had higher NIHSS score, were
more likely to have congestive heart failure, and were less likely to be current smokers or have CAD
(Supplementary Table S1).
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Age, y 65.4 ± 12.2 64.0 ± 12.0 71.0 ± 11.4 <0.001
Men 1793 (61.8) 1489 (64.2) 304 (52.2) <0.001
NIHSS score at admission 3.0 (1.0, 6.0) 2.0 (1.0, 4.0) 8.0 (4.0, 15.0) <0.001
Risk factors
Hypertension 2164 (74.6) 1712 (73.8) 452 (77.7) 0.057
Diabetes mellitus 920 (31.7) 728 (31.4) 192 (33.0) 0.459
Hypercholesterolemia 622 (21.4) 486 (21.0) 136 (23.4) 0.205
Current smoking 717 (24.7) 622 (26.8) 95 (16.3) <0.001
Congestive heart failure 119 (4.1) 92 (4.0) 27 (4.6) 0.465
Coronary artery disease 686 (23.6) 549 (23.7) 137 (23.5) 0.946
Cerebral artery
atherosclerosis 1727 (59.5) 1292 (55.7) 435 (74.7) <0.001
Peripheral artery disease 258 (8.9) 152 (6.6) 106 (18.2) <0.001
Laboratory findings
Glucose, mg/dL 143.5 ± 63.9 142.7 ± 63.2 1468 ± 66.0 0.168
HDL, mg/dL 42.8 ± 11.0 42.6 ± 10.8 43.4 ± 11.6 0.127
LDL, mg/dL 114.5 ± 38.6 114.7 ± 37.5 113.8 ± 42.5 0.651
Stroke subtype
LAA 587 (20.2) 440 (19.0) 147 (25.3) <0.001
CE 754 (26.0) 600 (25.9) 154 (26.5)
SVO 261 (9.0) 232 (10.0) 29 (5.0)
OC 72 (2.5) 58 (2.5) 14 (2.4)
UE 1227 (42.3) 989 (42.6) 238 (40.9)
Arm BP, mmHg
Right SBP 146.3 ± 23.5 146.7 ± 23.2 145.1 ± 24.6 0.147
Left SBP 145.3 ± 23.8 145.6 ± 23.6 144.0 ± 24.6 0.129
IAD 4.90 ± 6.51 4.71 ± 6.45 5.77 ± 7.15 0.001
Ankle BP, mmHg
Right SBP 164.5 ± 31.3 166.3 ± 30.1 157.7 ± 35.1 <0.001
Left SBP 163.6 ± 31.3 165.2 ± 30.4 157.2 ± 34.6 <0.001
IAND 9.23 ± 11.94 8.42 ± 10.82 12.65 ± 15.87 <0.001
ABI
Right ABI 1.111 ± 0.132 1.122 ± 0.118 1.071 ± 0.170 <0.001
Left ABI 1.105 ± 0.130 1.114 ± 0.118 1.069 ± 0.171 <0.001
ABID 0.063 ± 0.083 0.058 ± 0.077 0.086 ± 0.104 <0.001
Right ABI >1.30 58 (2.0) 44 (1.9) 14 (2.4) 0.434
Left ABI >1.30 44 (1.5) 31 (1.3) 13 (2.2) 0.113
Both ABI >1.30 18 (0.6) 14 (0.6) 4 (0.7) 0.818
Data are expressed as means ± standard deviations, medians [interquartile ranges], or numbers (%). ABI, ankle
brachial index; ABID, ankle brachial index difference; BP, blood pressure; CE, cardioembolism; DBP, diastolic blood
pressure; HDL, high density lipoprotein; IAD, systolic inter-arm blood pressure difference; IAND, systolic inter-ankle
blood pressure difference; LAA, large artery atherosclerosis; LDL, low density lipoprotein; mRS, modified Rankin
Scale; NIHSS, National Institutes of Health Stroke Scale; OC, other cause; SBP, systolic blood pressure; SVO, small
vessel occlusion; and UE, undetermined etiology.
In all study patients, 236 (8.1%) patients showed ABID ≥0.15, 450 (15.5%) had IAND ≥15 mmHg,
and 116 (4.0%) had IAD ≥15 mmHg. Among atherosclerotic diseases, CAA and PAD were independent
determinants of ABID ≥0.15 (CAA: odds ratio (OR), 1.718, 95% confidence interval (CI), 1.211-2.437;
PAD: OR, 22.124, 95% CI, 15.844-30.894) and IAND ≥15 mmHg (CAA: OR, 1.646, 95% CI, 1.281-2.114;
PAD: OR, 13.328, 95% CI, 9.876-17.987). However, only PAD was an independent determinant of IAD
≥15 mmHg (PAD: OR, 3.044, 95% CI, 1.890-4.904) (Table 2).
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Data were derived from the multivariable logistic regression analysis. ABID, ankle brachial index difference; CAD,
coronary artery disease; CAA, cerebral artery atherosclerosis; CI, confidence interval; IAD, systolic inter-arm blood
pressure difference; IAND, systolic inter-ankle blood pressure difference; NIHSS, National Institutes of Health
Stroke Scale; OR, odds ratio; and PAD, peripheral artery disease. *adjusted for sex, age, NIHSS score at admission,
hypertension, diabetes mellitus, hypercholesterolemia, current smoking, congestive heart failure, and stroke subtype.
ABID ≥0.15 and IAND ≥15 mmHg were more likely to have ABI >1.30 (all p values <0.001), but
not IAD ≥15 mmHg (Table 3). BaPWVs were well correlated with ABID, IAND, and IAD (with ABID,
r = 0.139, p < 0.001; with IAND, r = 0.207, p < 0.001; and with IAD, r = 0.121, p < 0.001) (Supplementary
Table S2).
Table 3. Relationship between IAD, IAND, ABID, and ABI >1.30.
Right ABI >1.30 Left ABI >1.30 Both ABI >1.30
n (%) p value n (%) p value n (%) p value
ABID
ABID <0.15 45 (1.7) 0.001 30 (1.1) <0.001 18 (0.7) 0.392
ABID ≥0.15 13 (5.5) 14 (5.9) 0 (0.0)
IAND
IAND <15 mmHg 36 (1.5) <0.001 27 (1.1) <0.001 16 (0.7) 1.000
IAND ≥15 mmHg 22 (4.9) 17 (3.8) 2 (0.4)
IAD
IAD <15 mmHg 55 (2.0) 0.503 42 (1.5) 0.695 17 (0.6) 0.521
IAD ≥15 mmHg 3 (2.6) 2 (1.7) 1 (0.9)
ABI, ankle brachial index; ABID, ankle brachial index difference; IAD, systolic inter-arm blood pressure difference;
and IAND, systolic inter-ankle blood pressure difference.
3.2. Poor Functional Outcome
All patients with (n = 2901) and without PAD (n = 2643) were separately analyzed. In all study
patients, poor outcome was independently associated with ABID (OR, 5.289, 95% CI, 1.723-16.236)
and cutoff of ABID ≥0.15 (OR, 1.920, 95% CI, 1.361-2.708). Poor outcome was also independently
associated with IAND (OR, 1.015, 95% CI, 1.007-1.023) and cutoff of IAND ≥15 mmHg (OR, 1.818,
95% CI, 1.389-2.381). In patients without PAD, the cutoff of ABID ≥0.15 was independently associated
with poor outcomes (OR, 1.970, 95% CI, 1.175-3.302). IAND and cutoff of IAND ≥15 mmHg were
also independently associated with poor outcomes (IAND: OR, 1.025, 95% CI, 1.009-1.041; IAND
≥15 mmHg: OR, 1.665, 95% CI, 1.188-2.334). Conversely, IAD ≥15 mmHg was associated with poor
outcomes in the whole population (OR, 1.623, 95% CI, 1.011-2.605) but was not associated with poor
outcomes in patients without PAD (Table 4).
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Table 4. Predictors of poor outcome at 3 months.
All Patients (n = 2901) Patients without PAD (n = 2643)
OR (95% CI) p value* OR (95% CI) p value*
ABI
ABID 5.289 (1.723-16.236) 0.004 5.774 (0.948-35.151) 0.057
ABID ≥0.15 1.920 (1.361-2.708) <0.001 1.970 (1.175-3.302) 0.010
Ankle BP, mmHg
IAND 1.015 (1.007-1.023) <0.001 1.025 (1.009-1.041) 0.002
IAND ≥15 mmHg 1.818 (1.389-2.381) <0.001 1.665 (1.188-2.334) 0.003
Arm BP, mmHg
IAD 1.009 (0.995-1.024) 0.190 1.009 (0.991-1.027) 0.329
IAD ≥15 mmHg 1.623 (1.011-2.605) 0.045 1.337 (0.758-2.360) 0.316
Data were derived from the multivariable logistic regression analysis. ABI, ankle brachial index; ABID, ankle brachial
index difference; BP, blood pressure; CI, confidence interval; IAD, systolic inter-arm blood pressure difference;
IAND, systolic inter-ankle blood pressure difference; NIHSS, National Institutes of Health Stroke Scale; OR, odds
ratio; and PAD, peripheral artery disease. *adjusted for sex, age, NIHSS score at admission, hypertension, diabetes
mellitus, hypercholesterolemia, current smoking, congestive heart failure, coronary artery disease, cerebral artery
atherosclerosis, and stroke subtype.
3.3. All-Cause Mortality and MACEs
Study patients were followed up for a median of 3.1 (IQR, 1.6–4.7) years. A total of 622 patients
had MACEs (21.4%) including 496 all-cause deaths (17.1%) during the study period. In Kaplan–Meier
survival curves (Figure 2), higher all-cause mortality and MACEs (log-rank test; p < 0.001) were found
in patients with ABID ≥0.15 or IAND ≥15 mmHg (log-rank test; all p < 0.001). Higher all-cause
mortality (log-rank test; p = 0.007) and MACEs (log-rank test; p = 0.008) were also found in patients
with IAD ≥15 mmHg.
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 All Patients (n = 2901) 
 All-Cause Mortality  MACE  
 HR (95% CI) p value* HR (95% CI) p value* 
Figure 2. Kaplan–Meier survival analysis. (A) All-cause mortality; (B) major adverse cardiovascular
event according to ABID ≥0.15. (C) All-cause mortality; (D) major adverse cardiovascular event
according to IAND ≥15 mmHg. ABID; ankle-brachial index difference; IAND, systolic inter-ankle
blood pressure difference.
In multivariable Cox regression analysis, ABID and ABID ≥0.15 were independently associated
with all-cause mortality (ABID: hazard ratio (HR), 6.221, 95% CI, 2.973-13.018; ABID ≥0.15: HR, 1.567,
95% CI, 1.223-2.009) and MACEs (ABID: HR, 3.926, 95% CI, 1.906-8.087; ABID ≥0.15: HR, 1.416, 95% CI,
1.117-1.794). IAND and IAND ≥15 mmHg were also independently associated with all-cause mortality
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(IAND: HR, 1.013, 95% CI, 1.007-1.019; IAND ≥15 mmHg: HR, 1.616, 95% CI, 1.317-1.982) and MACEs
(IAND: HR, 1.010, 95% CI, 1.005-1.015; IAND ≥15 mmHg: HR, 1.380, 95% CI, 1.139-1.672).
In patients without PAD, ABID and ABID ≥0.15 were independently associated with all-cause
mortality (ABID: HR, 9.221, 95% CI, 3.013-28.220; ABID ≥0.15: HR, 1.524, 95% CI, 1.039-2.235) and
MACEs (ABID: HR, 6.605, 95% CI, 2.281-19.124; ABID ≥0.15: HR, 1.514, 95% CI, 1.058-2.166). IAND
and IAND ≥15 mmHg were also independently associated with all-cause mortality (IAND: HR, 1.017,
95% CI, 1.004-1.030; IAND ≥15 mmHg: HR, 1.516, 95% CI, 1.164-1.973) and MACEs (IAND: HR,
1.015, 95% CI, 1.004-1.027; IAND ≥15 mmHg: HR, 1.343, 95% CI, 1.051-1.716). Meanwhile, IAD was
associated only with the long-term occurrence of MACEs in all patients (HR, 1.010, 95% CI, 1.001-1.019),
but not in those without PAD (HR, 1.006, 95% CI, 0.993-1.018, p = 0.374) (Table 5).
Table 5. Predictors of long-term outcome.
All Patients (n = 2901)
All-Cause Mortality MACE
HR (95% CI) p value* HR (95% CI) p value*
ABI
ABID 6.221 (2.973-13.018) <0.001 3.926 (1.906-8.087) <0.001
ABID ≥0.15 1.567 (1.223-2.009) <0.001 1.416 (1.117-1.794) 0.004
Ankle BP, mmHg
IAND 1.013 (1.007-1.019) <0.001 1.010 (1.005-1.015) <0.001
IAND ≥15 mmHg 1.616 (1.317-1.982) <0.001 1.380 (1.139-1.672) 0.001
Arm BP, mmHg
IAD 1.009 (0.999-1.019) 0.068 1.010 (1.001-1.019) 0.027
IAD ≥15 mmHg 1.176 (0.810-1.708) 0.395 1.151 (0.820-1.617) 0.417
Patients without PAD (n = 2643)
All-Cause Mortality MACE
HR (95% CI) p value* HR (95% CI) p value*
ABI
ABID 9.221 (3.013-28.220) <0.001 6.605 (2.281-19.124) 0.001
ABID ≥0.15 1.524 (1.039-2.235) 0.031 1.514 (1.058-2.166) 0.023
Ankle BP, mmHg
IAND 1.017 (1.004-1.030) 0.010 1.015 (1.004-1.027) 0.010
IAND ≥15 mmHg 1.516 (1.164-1.973) 0.002 1.343 (1.051-1.716) 0.019
Arm BP, mmHg
IAD 1.007 (0.993-1.021) 0.333 1.006 (0.993-1.018) 0.374
IAD ≥15 mmHg 1.075 (0.681-1.697) 0.755 1.032 (0.682-1.563) 0.881
Data were derived from the cox proportional hazards regression analysis. ABI, ankle brachial index; ABID, ankle
brachial index difference; BP, blood pressure; CI, confidence interval; HR, hazard ratio; IAD, systolic inter-arm blood
pressure difference; IAND, systolic inter-ankle blood pressure difference; MACE, major adverse cardiovascular
event; NIHSS, National Institutes of Health Stroke Scale; and PAD, peripheral artery disease. *adjusted for sex,
age, NIHSS score at admission, hypertension, diabetes mellitus, hypercholesterolemia, current smoking, congestive
heart failure, coronary artery disease, cerebral artery atherosclerosis, and stroke subtype.
4. Discussion
We demonstrated that higher ABID and IAND were independently associated with poor short-term
functional outcomes, long-term MACE occurrence, and all-cause mortality in patients with acute
ischemic stroke. In particular, higher ABID and IAND had prognostic effects even in patients without
PAD. Meanwhile, IAD was associated with poor short-term outcomes and MACEs in all patients, but
not in those without PAD. These findings suggest that higher ABID and IAND have prognostic value
for both poor short- and long-term outcomes of acute ischemic stroke and are more sensitive than IAD
for predicting outcomes in acute ischemic stroke patients without PAD.
Primarily, increased ABID and IAND are attributable to the presence of PAD [17]. PAD affects
approximately 200 million people worldwide and is the third most common cause of atherosclerotic
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cardiovascular death after CAD and stroke [18]. Traditional cardiovascular risk factors (smoking,
hypertension, diabetes mellitus, and hypercholesterolemia) and advanced aging are important
determinants of PAD. Therefore, patients with PAD often have concomitant atherosclerosis on
the cerebral and coronary artery. In the Reduction of Atherothrombosis for Continued Health registry
involving 44 countries worldwide, 39% of patients with PAD had CAD, 10% had cerebral artery disease,
and 13% had both [19]. Accumulated systemic atherosclerosis worsens stroke prognosis [20]. Among
the atherosclerotic burdens, ABID and IAND were associated with CAA and PAD. In contrast, IAD
was only associated with PAD. It can be assumed that stroke patients with large ABID and IAND are
more likely to have additional cerebral atherosclerotic burden and may have a poorer prognosis.
To the best of our knowledge, no study has previously evaluated ABID as a prognosis predictor
in patients with acute ischemic stroke. ABI measurement is a well-established method to identify
patients with PAD. Low ABI is commonly defined as ABI <0.9 and provides good sensitivity (80%) and
excellent specificity (95%) to detect PAD [4]. ABI is also associated with poor initial stroke severity [21]
and predicts poor prognosis and mortality in patients with stroke [2]. However, several previous
studies have shown that low ABI was not sensitive enough to detect asymptomatic PAD in the general
population [22]. To detect PAD and predict stroke prognosis accurately, novel parameters besides ABI
should be developed. We found that ABID and IAND were independent and strong predictors of
MACEs and all-cause mortality in patients with acute ischemic stroke. Interestingly, ABID and IAND
remained to be significantly associated with poor short- and long-term outcomes in patients without
PAD. This finding suggests that ABID and IAND may provide additional information for patients with
subclinical or mild PAD. The strength of ABID might be related to the consideration of IAND and arm
BP simultaneously. In addition, ABID and IAND can be obtained and easily calculated during ABI
measurement in routine clinical practice.
In patients with stroke, IAD has been demonstrated to be associated with recurrent stroke [23],
poor prognosis [24], and mortality [6]. However, some patients undergo dialysis with one arm because
of end-stage renal disease, making it difficult to measure IAD. In addition, IAD (and ABI) may be
“pseudonormal” when a patient has severe stenosis in both arms and in one leg. In contrast, IAND can
be calculated without BP measurement in the arm and provide consistent data [3]. Several studies
showed the increased usefulness of IAND and ABI relative to IAD. One study showed that IAND
could better predict both overall and cardiovascular mortality than IAD in elderly patients [3]. ABI
exhibits better association with cardiovascular outcomes than IAD in patients with type 2 diabetes [25].
However, no study has reported the comparison between IAND and IAD in patients with acute
ischemic stroke.
Because lower limbs are more prone to be affected by PAD than upper limbs, IAND could be a
better predictor of PAD than IAD [26]. High IAND was associated with increased left ventricular mass
index [27] and arterial stiffness [28] and also predicted mortality in the elderly people [3]. Similarly,
large ABID provided the prognostic value for mortality in patients undergoing chronic hemodialysis [5].
These findings suggest that the cardiovascular risk was higher in patients with lower extremity PAD
than in those with upper extremity PAD [29]. Therefore, the circulatory burden assumed from the
heart to the ankles may be greater than that from the heart to the arms.
Endothelial dysfunction [26], calcification burden [30], and arterial stiffness [27] are more frequent
in the lower extremities than in the upper extremities. The degree of endothelial dysfunction in leg
circulation is related to PAD severity. Endothelial dysfunction of leg circulation may occur before
the impairment of forearm circulation in PAD [26]. Our data showed that high ABID and IAND
were more likely to have ABI >1.30 than IAD. High ABI (i.e., ABI >1.30) is generally believed to
occur because of medial arterial calcification and may be a marker for vascular stiffness [4]. High
ABI was associated with an increase in both overall and cardiovascular mortality in patients with
chronic kidney disease undergoing hemodialysis [31] and in the general population [32]. PWV and
ABI are both atherosclerotic markers. ABI reflects stenosis or peripheral artery obstruction, whereas
PWV represents arterial stiffness [5]. ABID, IAND, and IAD was positively correlated with baPWV.
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The correlation coefficient was highest in IAND, followed by ABID and IAD. In patients undergoing
hemodialysis, high PWV and low ABI are significantly associated with mortality [33]. Therefore, ABID
and IAND could be more influenced by endothelial dysfunction, systemic atherosclerosis, calcification
burden, and arterial stiffness than IAD, which may be related to more frequent PAD in the lower
extremities [25,26,28,29].
This study has several limitations. First, radiological studies to detect atherosclerosis in the
lower extremities were not routinely performed. A correlation study between apparent atherosclerosis
and IAND or ABID might be helpful for better understanding [4,17]. Second, multiple, automatic,
and simultaneous assessments are recommended for accurate BP difference measurement rather than
single, manual, and sequential evaluation methods [34]. We used an automatic and simultaneous
measurement device, but BP difference was investigated only once during the ABI measurement,
and additional follow-up data were limited. Third, BP differences in this study focused on SBP, rather
than DBP. Additional analysis was performed with DBP data, which found that the prognostic effect of
DBP was not different from that of SBP (Supplementary Tables S3 and S4). Fourth, our findings may
not be generalized to other populations or cohorts because our study population is limited to Korean
patients. Fifth, the stroke standard treatment guidelines were updated and changed several times
during the study period. Lastly, a total of 921 patients were excluded from the analysis. Among them,
patients who did not undergo ABI measurements were mostly excluded. Therefore, the possibility of
selection bias exists because of the retrospective study design; however, consecutive patients were
included, and a relatively large sample size was analyzed.
5. Conclusions
This study suggests that high ABID and IAND are associated with poor short-term outcomes,
long-term MACE occurrence, and all-cause mortality in patients with acute ischemic stroke. In addition,
ABID and IAND predict post-stroke outcomes, even in patients without PAD. Therefore, ABID and
IAND can be simple and reliable methods for identifying patients with an increased risk of poor short-
and long-term outcomes in acute ischemic stroke.
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